The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

J Immunother Cancer · 2016 · PMC5168808 · PMID 28018601

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, in 2010 gemtuzumab ozogamicin was voluntary withdrawn after a phase 3 trial (SWOG S0106) in newly diagnosed AML based showed a trend toward an increased mortality in the gemtuzumab ozogamicin arm [ 180 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.